# Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

> **NCT03883906** · PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 30 (actual)

## Conditions studied

- Allogeneic Stem Cell Transplant
- Viral Infection

## Interventions

- **BIOLOGICAL:** Viral Specific T-cells (VSTs)

## Key facts

- **NCT ID:** NCT03883906
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-16
- **Primary completion:** 2020-10-31
- **Final completion:** 2021-10-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883906, "Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03883906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*